Table 3.
Analysis of factors that may affect the survival of patients with KRAS wild‐type colorectal carcinoma (n = 112)
| Characteristics | P (univariate) | P (multivariate) | HR |
|---|---|---|---|
| Age (years) | |||
| <50 vs ≥50 | 0.48 | NA | NA |
| Gender | |||
| Male vs female | 0.36 | NA | NA |
| Performance status | |||
| 0 vs 1, 2 | 0.21 | NA | NA |
| Primary tumor | |||
| Colon vs rectum | 0.45 | NA | NA |
| VEGF expression level | |||
| ≥10% vs <10% positive cells | 0.02 | 0.06 | 1.68 |
| At least one tumor ≥6 cm | |||
| Presence vs absence | 0.15 | NA | NA |
| Histologic differentiation | |||
| Good–moderate vs poor | 0.13 | NA | NA |
| Lymphovascular invasion | |||
| Presence vs absence | 0.06 | NA | NA |
| Metastasis at diagnosis | |||
| Yes vs No | 0.03 | <0.01 | 3.82 |
| Serum CEA level (ng/mL) | |||
| ≤6 vs >6 | 0.34 | NA | NA |
| Second‐line chemotherapy | |||
| No vs yes | 0.03 | 0.02 | 2.32 |
| EGFR R521K polymorphism | |||
| G/G (wild‐type) vs G/A or A/A | 0.03 | 0.02 | 2.41 |
| ERCC1 codon 118 genotype | |||
| C/T or T/T vs C/C | 0.01 | <0.01 | 4.51 |
| XPD codon 751 status | |||
| Lys/Gln vs Lys/Lys | 0.02 | <0.01 | 3.35 |
| TSER 28‐bp polymorphism | |||
| 2R/2R+2R/3R vs 3R/3R | 0.18 | NA | NA |
bp, base pair; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; ERCC1, excision repair cross‐complementing group 1; HR, Cox hazard ratio; NA, not analyzed; TSER, 5′‐enhancer region of the thymidylate synthase gene; VEGF, vascular endothelial growth factor; XPD, xeroderma pigmentosum group D.